Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BioLineRx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

BioLineRx şirketinin toplam hissedar öz sermayesi $14.0M ve toplam borcu $29.4M olup, bu da borç-öz sermaye oranını 210.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $64.6M ve $50.6M dir.

Anahtar bilgiler

210.6%

Borç/özkaynak oranı

US$29.45m

Borç

Faiz karşılama oranı	n/a
Nakit	US$40.06m
Eşitlik	US$13.98m
Toplam yükümlülükler	US$50.62m
Toplam varlıklar	US$64.60m

Son finansal sağlık güncellemeleri

Recent updates

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

Apr 02

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

Aug 25

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Apr 05

Is BioLineRx (TLV:BLRX) A Risky Investment?

Jun 17

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Feb 26

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Oct 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BLRX 'nin kısa vadeli varlıkları ( $49.1M ) kısa vadeli yükümlülüklerini ( $30.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: BLRX şirketinin kısa vadeli varlıkları ( $49.1M ) uzun vadeli yükümlülüklerini ( $20.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BLRX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: BLRX şirketinin borç/öz sermaye oranı son 5 yılda 21.5% seviyesinden 210.6% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BLRX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: BLRX serbest nakit akışı her yıl % { 0.1 1.3 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

BioLineRx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Is BioLineRx (TLV:BLRX) A Risky Investment?

Recent updates

New major risk - Revenue and earnings growth

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

New major risk - Financial position

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

New major risk - Share price stability

New major risk - Revenue and earnings growth

BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production

Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer

BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?

New minor risk - Market cap size

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

New major risk - Shareholder dilution

BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023

New minor risk - Shareholder dilution

BioLineRx Ltd. announced that it has received $14.6 million in funding

New minor risk - Market cap size

Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac)

BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

New major risk - Financial position

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023

BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

Less than half of directors are independent

BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

Is BioLineRx (TLV:BLRX) A Risky Investment?

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022

Less than half of directors are independent

BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Forecast breakeven pushed back to 2024

BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

BioLineRx Ltd. to Report Fiscal Year 2020 Results on Feb 23, 2021

New 90-day high: ₪0.82

BioLineRx Ltd. Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

New 90-day high: ₪0.66

BioLineRx Ltd. to Report Q3, 2020 Results on Nov 23, 2020

BioLineRx Ltd. Announces Initiation of Phase 1B Clinical Trial in Patients with Acute Respiratory Distress Syndrome Secondary to Covid-19 and Other Respiratory Viral Infections

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization

New 90-day low: ₪0.36

New 90-day low: ₪0.37

BioLineRx Ltd. has completed a Follow-on Equity Offering.

BioLineRx Ltd. to Report Q2, 2020 Results on Aug 06, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço